Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Differentially Expressed Genes upon Knockdown of ZRANB1 or EZH2 in LM2 Cells

ABSTRACT: Differentially Expressed Genes upon Knockdown of ZRANB1 or EZH2 in LM2 Cells

PROVIDER: PRJNA414117 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Differentially Expressed Genes upon Knockdown of ZRANB1 or EZH2 in LM2 Cells

Project description:EZH2, the catalytic component of the Polycomb repressive complex 2 (PRC2), silences gene transcription by methylating histone H3 at lysine 27. Recently we identified ZRANB1 as the EZH2 deubiquitinase. ZRANB1 binds, deubiquitinates, and stabilizes EZH2. To determine whether ZRANB1 is a functional regulator of EZH2, we performed RNA-Seq analysis to compare the effect of ZRANB1 knockdown or EZH2 knockdown on global gene expression.

2018-04-18 | GSE104910 | GEO

Differentially expressed genes in CSRP2BP knockdown HTR-8 cells

Project description:Differentially expressed genes in CSRP2BP knockdown HTR-8 cells

| PRJNA742652 | ENA

Differentially expressed miRNAs in colorectal cancer

Project description:Differentially expressed miRNAs in colorectal cancer

| PRJNA658901 | ENA

Differentially expressed genes following ARID1A depletion

Project description:Differentially expressed genes following ARID1A depletion

| PRJNA477786 | ENA

Human breast cancer LM2 cell lines: control vs. MTDH knockdown

Project description:Transcriptional profiling of human breast cancer cell line LM2, a subline of MDA-MB-231 highly metastatic to lung when injected to nude mice, to identify the genes that are regulated after the metastasis gene metadherin is knocked down. Keywords: Genetic modification Empty pSuper vector control cells were compared to the cells transfected with the MTDH knockdown shRNA construct. Two cultured conditions were studied: the LM2 cancer cells were cultured alone or on top of a monolayer of human lung endothelial HMVEC-L cells. Three arrays for each sample.

2010-05-26 | E-GEOD-9187 | biostudies-arrayexpress

Human breast cancer LM2 cell lines: control vs. MTDH knockdown

2008-02-01 | GSE9187 | GEO

miR-126 over-expression in highly metastatic LM2 breast cancer cells.

Project description:miR-126 were over-expressed using the miR-Vec system in highly metastatic LM2 cells. The LM2 cell line are described in detail in Minn et al. Nature 2005 This approach was used to conduct an unbiased search for specific miR-126 target genes in breast cancer cells.

2011-12-16 | GSE23905 | GEO

Gene expression profiling of two DLBCL cell lines upon shRNA mediated knockdown of EZH2

Project description:We studied transcriptional changes by Affymetrix human microarrays in 2 DLBCL cell lines as a result of shRNA mediated knockdown of EZH2. In eukaryotes, epigenetic post-translational modification of histones is critical for regulation of chromatin structure and gene expression. EZH2 is the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2) and is responsible for repressing target gene expression through methylation of histone H3 on lysine 27 (H3K27). Over-expression of EZH2 is implicated in tumorigenesis and correlates with poor prognosis in multiple tumor types. Recent reports have identified somatic heterozygous mutations of Y641 and A677 residues within the catalytic SET domain of EZH2 in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The Y641 residue is the most frequently mutated residue, with 22% of GCB (Germinal Cell B-cell) DLBCL and FL harboring mutations at this site. These lymphomas exhibit increased H3K27 tri-methylation (H3K27me3) due to altered substrate preferences of the mutant enzymes. However, it is unknown whether direct inhibition of EZH2 methyltransferase activity alone will be effective in treating lymphomas carrying activating EZH2 mutations. Herein, we demonstrate that GSK126, a potent, highly-selective, SAM-competitive, small molecule inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes. GSK126 effectively inhibits the proliferation of EZH2 mutant DLBCL cell lines and dramatically inhibits the growth of EZH2 mutant DLBCL xenografts in mice. Together, these data demonstrate that pharmacological inhibition of EZH2 activity may provide a promising treatment for EZH2 mutant lymphoma. Pfeiffer and KARPAS-422 cells were treated with either shRNA targeting EZH2 (shEZH2) or a non targeting control (shNTC) for 10 days.

2012-10-12 | E-GEOD-41239 | biostudies-arrayexpress

Identification of differentially expressed microRNAs in OLF

Project description:Identification of differentially expressed microRNAs in OLF

| PRJNA416005 | ENA

Identification of differentially expressed circRNAs in OLF

Project description:Identification of differentially expressed circRNAs in OLF

| PRJNA416002 | ENA